London Co. of Virginia Acquires 44,610 Shares of Enovis Corporation $ENOV

London Co. of Virginia raised its holdings in Enovis Corporation (NYSE:ENOV) by 12.0% during the 1st quarter, HoldingsChannel.com reports. The fund owned 416,582 shares of the company’s stock after buying an additional 44,610 shares during the period. London Co. of Virginia’s holdings in Enovis were worth $9,477,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Arax Advisory Partners purchased a new stake in shares of Enovis during the fourth quarter valued at $29,000. EverSource Wealth Advisors LLC increased its stake in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the period. GAMMA Investing LLC lifted its holdings in Enovis by 353.5% during the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after buying an additional 1,446 shares in the last quarter. Danske Bank A S bought a new stake in Enovis during the 3rd quarter valued at about $64,000. Finally, iSAM Funds UK Ltd purchased a new stake in Enovis in the 3rd quarter valued at about $80,000. 98.45% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider Oliver Engert bought 1,200 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were acquired at an average price of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider owned 51,840 shares of the company’s stock, valued at $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders acquired a total of 4,200 shares of company stock worth $92,084 in the last ninety days. 2.90% of the stock is owned by corporate insiders.

Enovis Trading Up 3.8%

NYSE ENOV opened at $27.05 on Friday. Enovis Corporation has a one year low of $19.14 and a one year high of $34.28. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -1.36 and a beta of 1.39. The company’s 50-day simple moving average is $23.65 and its two-hundred day simple moving average is $23.78.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. During the same quarter in the prior year, the company earned $0.81 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts forecast that Enovis Corporation will post 3.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ENOV shares. William Blair initiated coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating on the stock. Evercore set a $32.00 price target on Enovis in a report on Monday, July 6th. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Wells Fargo & Company reduced their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.71.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.